BEIJING—China-based Yipinhong Pharmacy Co., Ltd (SHE: 300723) has announced that its novel drug AR882 has received fast-track designation from the US Food and Drug Administration (FDA) for the treatment of visible tophi in patients with gout. This Category 1 drug, co-developed with US firm Arthrosi Therapeutics Inc., is a next-generation uric acid transporter (URAT1) inhibitor that promises to be a significant advancement in gout management.
Designed to reduce serum uric acid (sUA) levels, AR882 works by inhibiting the reabsorption of uric acid and normalizing the excretion of uric acid salts in urine. This highly efficient and selective inhibitor is intended to provide a targeted approach to treating gout and gouty tophi, a debilitating condition characterized by the formation of urate crystals in joints and soft tissues.
The joint venture between Yipinhong and Arthrosi holds all commercialization rights to AR882 in Greater China, including mainland China, Hong Kong, Taiwan, and Macau. This strategic partnership aims to leverage the strengths of both companies to bring innovative therapies to patients in the region and potentially expand the drug’s reach globally.
The FDA’s fast-track designation is a significant milestone for AR882, as it facilitates a more expedited review process for drugs that treat serious conditions and fill an unmet medical need. This designation underscores the potential impact of AR882 on improving the standard of care for gout patients and the commitment of Yipinhong and Arthrosi to advancing therapeutic options in the field of rheumatology.- Flcube.com
